Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, February 15, 2020

Triphenylphosphonium (TPP)‐Based Antioxidants: A New Perspective on Antioxidant Design

This sentence in the full research is important. 

undergone preliminary clinical trials and has provided promising results in
a variety of disease models, including stroke, autoimmune arthritis

Meaning your doctors and stroke hospitals should IMMEDIATELY be contacting researchers to get  followup human research done with protocols created. If not, then they need to be fired, starting with the board of directors.

 

Triphenylphosphonium (TPP)‐Based Antioxidants: A New Perspective on Antioxidant Design

First published: 05 February 2020


Abstract

Mitochondrial oxidative damage and dysfunction contribute to a wide range of human diseases. Considering the limitation of conventional antioxidants and that mitochondria are the main source of reactive oxygen species (ROS) which induce oxidative damage, mitochondria‐targeted antioxidants which can selectively block mitochondrial oxidative damage and prevent various types of cell death have been widely developed. As a lipophilication, triphenylphosphonium (TPP) has been commonly used in designing mitochondria‐targeted antioxidants. Conjugated with the TPP moiety, antioxidants can achieve more than 1000‐fold higher mitochondrial concentration depending on cell membrane potentials and mitochondrial membrane potentials. Herein we discuss the deficiencies of conventional antioxidants and the advantages of mitochondrial targeting, and review various types of TPP‐based mitochondria‐targeted antioxidants. These provide theoretical and background support for the design of new anti‐oxidant.


No comments:

Post a Comment